NexgenRx Q2 FY26 net income more than doubles to 993,095; revenue rises 20.8% to 5.16 million

• NexgenRx posted Q2 revenue of $5.16 million, up 20.8% year over year.
• Net income more than doubled to $993,095; EBITDA rose 92.5% to $1.21 million.
• Higher transaction fee revenue on increased transaction volumes helped lift results.
• At June 30, total assets climbed to $46 million; shareholders’ equity strengthened to $9.4 million.
• Declared a $0.005 per-share dividend, payable on or before Aug. 31 to holders of record Aug. 28.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NexgenRX Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608201655ACCESSWRNAPR_____1210078) on August 20, 2026, and is solely responsible for the information contained therein.